GO
Loading...

Cramer's Heartfelt Speculative Trade

Friday, 18 Mar 2011 | 10:35 PM ET
Speculation Playbook
Cramer teaches you how to practice safe speculation.

In this volatile market, Cramer on Friday recommended home gamers invest in domestic companies with little international exposure, no generic competition and have the support of President Barack Obama.

Take medical device stocks, for example. Cramer thinks it's a great place to speculate given the U.S.'s aging population. After all, there are 78 million baby boomers, who may eventually need joint or hip replacements, pacemakers and the like. In addition, the U.S. Food and Drug Administration has begun approving devices at a faster pace than it once had, Cramer said.

Last week, Cramer suggested Stryker, a medical technology company based in Kalamazoo, Mich. On Friday, the "Mad Money" host wanted to examine small cap names.

In the cardiac group, Cramer's fave spec pick is Heartware International. The Framingham, Mass.-based company makes devices used in patients awaiting heart transplants.

Hearth disease currently affects 5 million people in the U.S. and costs its health care system roughly $37 billion, Cramer said. What's worse is that some 300,000 people die from heart failure every year, he added. Heartware makes a left-ventricular assist device, which helps keep people alive while they wait for their heart surgery.

Out on a Limb?
Cramer revisits medical devices in an attempt to deliver some profits.

There is another play on the LVAD, Cramer said. Pleasanton, Calif.-based Thoratec also makes LVAD, but its product has already saturated the $200 million bridge-to-transplant market in the U.S.

Cramer thinks Heartware is the better play, though. Its HVAD product gained approval from Europe in 2009 and it expects a decision from the FDA by the fourth quarter. He thinks FDA approval is likely being as it's already had a successful trial run. HVAD is seen by many as the superior product, Cramer said. Being as it's a smaller device, it is easier to implant. According to a study, Cramer said the survival rate for Heartware's product was 90 percent versus Thoratec's 78 percent.

But that's not all. Cramer has another small cap speculative play in this space. To find out which stock he's recommending, watch the video directly above.

Injection of Profits?
Cramer focuses on spec investments that aren't tied to concerns about Japan and the Middle East.

Wait! Cramer's not done. He has yet another spec for all of the home gamers. Check out the video below to see what this last play is all about.




















Call Cramer: 1-800-743-CNBC

Questions for Cramer? madmoney@cnbc.com

Questions, comments, suggestions for the Mad Money Web site? madcap@cnbc.com

  Price   Change %Change
HTWR
---
SYK
---
THOR
---

Contact Mad Money

  • Showtimes

    Monday - Friday 6p ET
  • Jim Cramer is host of CNBC's "Mad Money" and co-anchor of the 9 a.m. ET hour of CNBC's "Squawk on the Street."

Mad Money Features

  • Grab the latest CNBC gear from the NBCUniversal Store!

  • Get a behind-the-scenes look at how Cramer formulates his investment advice. "Inside the Madness" is a column, which features e-mails and more with Cramer and his researcher Nicole Urken.

  • You’ve always wanted to hit the “Hallelujah!” button. Here’s your chance.